Open company graph database — free web & API
Login

Kyowa Kirin USA Holdings, Inc.

Kyowa Kirin, Inc.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
5,161
Related companies
28
§01

Basic information

BASIC
Head office
1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan, Otemachi Financial City Gran Cube
Chief executive
Abdul Malik
Capital
26,745,000,000 JPY (267 100 millionJPY)
Employees (non-consolidated)
Employees (consolidated)
5,161 people
Start date
1949-07-01
End date
§02

Websites

3 DOMAINS
§03

Business

1
Research, development, manufacturing, sales, and import/export of pharmaceutical products for medical use.
§04

Related companies

28 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Kyowa Kirin Ltd.
Group Parent
Kirin Business Systems Inc.
Group
Kirin Bio Material Co., Ltd.
Group
Kyowa Kirin Australia Pty Ltd (Australia)
Group
Orchard Therapeutics (London)
Group
Taiwan Kyowa Kirin Co., Ltd.
Group Subsidiary
Killing Group Logistics Co., Ltd.
Group
Kirin Business Experts Co., Ltd.
Group
New Belgium Brewing Company, Inc.
Group
Kirin Engineering Co., Ltd.
Group
Kirin Welfare Foundation
Group
Brooklyn Brewery Corporation
Group
Kirin and Communications Co., Ltd.
Group
Orchard Therapeutics (Boston)
Group Subsidiary
Omron Kirin Technosystem Co., Ltd.
Group
BioWa, Inc.
Group Subsidiary
Coca-Cola Beverages Northeast, Inc.
Group
Kirin Brewery of America, LLC
Group
Kirin Holdings Singapore Pte, Limited (Singapore) Open in a separate window
Group
Kyowa Kirin CA
Group
Kyowa Kirin Pharmaceutical Development
Group
Kyowa Kirin Pharmaceutical Research
Group
Kyowa Kirin USA Holdings, Inc.
Group
Lion Nathan USA Inc.
Group
Little World Beverages, Inc.
Group
Kirin Echo Co., Ltd.
Group
Kirin Office Service Co., Ltd.
Group
Kyowa Kirin Co., Ltd. (Korea)
Group Subsidiary
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

76 EVENTS

The predecessor of Japan Brewery Company, Japan Brewery Company (hereafter JBC), was established. Later, T.B. Graber also served as an executive.Sources

JBC signed a sales agreement with Meijiya's Isano Kei and released a German-style lager beer under the brand name "Kirin Beer".Sources

Dr. Shibasaburo Kitasato and Dr. Bering discovered that the serum obtained from an animal infected with diphtheria was effective in the treatment of diphtheria and tetanus; they established serum therapy.Sources

Japan Brewery Company was reorganized into The Japan Brewery Company (hereafter also JBC).Sources

Establishment of Kirin Brewery Co., Ltd.Sources

Inherited JBC's business and established Kirin Brewery Co., Ltd.Sources

Kanzaki Factory (later Kirin Beer Amagasaki Factory) completed (operations ceased in 1996).Sources

"Kirin Black Beer" released (production ended in 1998).Sources

Acquisition agreement with Toyo Brewing Co., Ltd. finalized; Sendai Factory (now Kirin Beer Sendai Factory) launched.Sources

Yokohama Yamanote Factory collapsed due to the Great Kanto Earthquake.Sources

Kirin Brewery changed its head office registration from Yokohama City Yamanote-cho to Yokohama City Kanagawa-ku Koayama-cho, Kaidai-dori.Sources

Completion of Yokohama New Factory (now Kirin Beer Yokohama Factory)Sources

Kirin Beer terminated the exclusive sales agreement with Meijiya, established a sales department, and began sales.Sources

Kirin Beer completed a soft drink factory within the Yokohama factory.Sources

Release of the carbonated beverage 'Kirin Lemon'.Sources

Kirin Beer changed the registered headquarters location from 1-1 Kaido-dori, Koayama-cho, Kanagawa-ku, Yokohama City to Ikimaki, Tsurumi-ku, Yokohama City.Sources

Kirin Beer completed a pharmaceutical plant within the Yokohama factory, producing yeast agents and the like.Sources

Release of 'Kirin Stout' (production ceased in 2008).Sources

Showa Kirin Beer Co., Ltd. was established in Korea (business transferred in 1945).Sources

Completion of Showa Kirin Beer Nongo factory (business transferred in 1945).Sources

Manchuria Beer Co., Ltd. was established through joint investment with Dai Nippon Beer (business transferred in 1937).Sources

Completion of Manchuria Beer Second Factory (business transferred in 1937).Sources

Kirin Beer completed the Tomita Distillery factory (transferred to K.W.C. Co., Ltd. in 1992).Sources

Kirin Beer completed the Hiroshima factory (operations ceased in 1998).Sources

Reorganized the Harutori Transport Company, which handled logistics for Kirin Beer Yokohama Factory, into Harutori Automobile Transport Co., Ltd. (now Kirin Group Logistics Co., Ltd.)Sources

Limited Company Rinpo Trading Co. (now Kirin Echo Co., Ltd.) established.Sources

Decided to discontinue beer brand trademarks; thereafter, labels were unified under 'Beer'.Sources

Kirin Beer opened the Kirin Research Institute (now Kirin Holdings Co., Ltd. Kirin Central Research Institute, etc.).Sources

Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.Sources

Acquired shares of Kinko Trading Co., Ltd., which operates beer halls.Sources

Revived the 'Kirin Beer' trademark and began sales.Sources

Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).Sources

Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C. Invention of the process of L-glutamic acid production by fermentation (a world first).Sources

Gerald Edelman and Rodney Porter determined the molecular structure of antibodies.Sources

Initiation of full-scale involvement in the pharmaceutical business. Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.Sources

Release of 5-FU, an anticancer drug.Sources

Release of Leunase, an anticancer drug.Sources

César Milstein, Georges Köhler and Niels Kaj Jerne established the hybridoma technology, which is a technology for producing monoclonal antibodies.Sources

Dr. Susumu Tonegawa discovered the genetic principle for the generation of antibody diversity.Sources

The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.Sources

The world's first therapeutic antibody "muromonab" was approved.Sources

Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).Sources

Release of ESPO®, an erythropoietin (EPO) drug.Sources

Antibody engineering technologies were established.Sources

Release of GRAN®, G-CSF drug. Release of Coniel, a remedy for hypertension and angina pectoris.Sources

Establishment of fully human antibody production technology.Sources

Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.Sources

Japan’s first therapeutic antibody "tocilizumab" was approved.Sources

The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP®, a long-acting erythropoietic stimulating drug. Established COMPLEGENT®, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary. Capital alliance between Kyowa Hakko Group and Kirin Group.Sources

Release of REGPARA®, a drug for secondary hyperparathyroidism. Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd. Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma.Sources

Introduced 'Commitment to Life'.Sources

Kirin Holdings Co., Ltd. and Kokura Dairy Co., Ltd. discovered a lactobacillus that activates immune cells responsible for virus infection defense (later named 'Plasma Lactobacillus').Sources

Acquired ProStrakan Group plc.Sources

Launch of Poteligeo® in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL).Sources

Launch of NOURIAST® tablets 20 mg in Japan, a novel antiparkinsonian agent.Sources

ProStrakan Completes Acquisition of Archimedes. Launch of Sustained-Duration G-CSF Product G-LASTA® in Japan.Sources

Kyowa Hakko Bio Thailand’s local subsidiary has completed its amino acid production plant.Sources

Rebranding Western Pharmaceutical Subsidiaries to 'Kyowa Kirin'. Launch of LUMICEF® for Psoriasis Treatment in Japan.Sources

Actively strengthening corporate governance that supports management, and continuing further improvements to date.Sources

In line with the new KV2021 policy, we sold Kirin Brazil Co., which had been experiencing declining performance.Sources

We launched a new brand featuring the group’s proprietary ingredient, ‘plasma lactic acid bacteria’. In 2020, it was the first functional food to receive approval for immune function, and sales continue to grow.Sources

Crysvita® approved in the US and Europe for X-linked hypophosphatemia. Poteligeo® approved in the US and Europe for mycosis fungoides (MF) and Sézary syndrome (SS).Sources

Trade name changed to Kyowa Kirin Co., Ltd. Crysvita® launched in Japan for FGF23-related Hypophosphatemic Rickets and Osteomalacia. Nourianz™ launched in the US for Parkinson's disease.Sources

We formulated the ‘CSV Purpose’ guideline to co‑create society and value for sustainable growth.Sources

Kirin Holdings established a new site, the iMUSE Health Science Factory, for manufacturing lactic acid bacteria raw materials, and began production.Sources

In the health science field, we partnered with FANCL to supplement capabilities not present in the group.Sources

Poteligeo® launched in Europe for mycosis fungoides (MF) and Sézary syndrome (SS). Crysvita® approved in the US for tumor-induced osteomalacia (TIO).Sources

The claim ‘supporting the maintenance of immune function in healthy individuals’ was the first time the consumer agency accepted a submission under the functional food labeling system.Sources

New Vision toward 2030. Agreement with Amgen on KHK4083 development. Support for TCFD recommendations.Sources

Global DE&I Statement adopted. Launch of G-Lasta® Subcutaneous Injection 3.6 mg BodyPod in Japan. Completion of Q-TOWER analysis facility.Sources

More than 100 therapeutic antibodies have been approved in Japan, Europe, and the United States.Sources

PHOZEVEL® approved in Japan. Acquisition of Orchard Therapeutics announced.Sources

Aiming to become a leading health science company in Asia‑Pacific, we made the Australian company Blackmores, which operates in supplements and health foods, a subsidiary.Sources

Lenmeldy™ approved and launched in the US. New biologics manufacturing plant planned in North Carolina. Collaboration with Kura Oncology on menin inhibitor ziftomenib.Sources

Completion of HB7 Building at Takasaki Plant. FDA approval and US launch of KOMZIFTI™ (ziftomenib) for AML.Sources

Leveraging organizational capabilities cultivated across diverse business areas, we formulated the new long‑term management concept ‘Innovate2035!’ to sustain growth for the next 100 years through autonomous business growth and synergistic use of group assets. Our vision is to ‘keep the world healthier by continuously innovating as a CSV‑leading company powered by people and technology,’ and we are working toward realizing this.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑